Skip to content Skip to footer
Subscribe Now
PharmaShots Interview GSK’s Tom Corbridge Shares Insights on Nucala as At-Home Treatment Option for Children with Severe Eosinophilic Asthma
VIEWPOINTS

PharmaShots Interview: GSK’s Tom Corbridge Shares Insights on Nucala as At-Home Treatment Option for Children with Severe Eosinophilic Asthma

In an interview with PharmaShots, Tom Corbridge, Senior Medical Lead at GSK shared his views on the approval of its anti-IL-5 biologic NUCALA (mepolizumab) in a 40 mg pre-filled syringe for appropriate children aged 6 to 11 years old with severe eosinophilic asthma (SEA) Shots: Nucala can now be given by a child’s HCPs or administered…
May 4, 2022

Read more

PharmaShots Interview X4 Pharmaceuticals’ Paula Ragan Shares Insights on Mavorixafor for the Treatment of Multiple Immunodeficiencies
VIEWPOINTS

PharmaShots Interview: X4 Pharmaceuticals’ Paula Ragan Shares Insights on Mavorixafor for the Treatment of Multiple Immunodeficiencies

In an interview with PharmaShots, Paula Ragan, Ph.D., CEO, and President at X4 Pharmaceuticals shared her views on the data of Mavorixafor which showed increased immune cell levels regardless of patients having a CXCR4 mutation to treat multiple immunodeficiencies, presented at ASH 2021 Shots: The ongoing long-term extension arm of the P-II trial evaluates Mavorixafor (CXCR4 antagonist) in patients with WHIM syndrome. The therapy continues…
May 3, 2022

Read more

PharmaShots Interview Janssen’s Mark Wildgust Shares Insights on Imbruvica for Chronic Lymphocytic Leukemia and Darzalex for Multiple Myeloma
VIEWPOINTS

PharmaShots Interview: Janssen’s Mark Wildgust Shares Insights on Imbruvica for Chronic Lymphocytic Leukemia and Darzalex for Multiple Myeloma

In an interview with PharmaShots, Mark Wildgust, Vice President, Global Medical Affairs, Oncology at Janssen shared his views on the data of Imbruvica in P-III (GLOW) and P-II (CAPTIVATE) studies for the treatment of CLL or SLL and also highlighted the results of Darzalex in the P-II (GRIFFIN) & P-III (MAIA) study for multiple myeloma The P-III (GLOW) and P-II (CAPTIVATE) studies evaluating Imbruvica + venetoclax (I+V) as a…
May 2, 2022

Read more

PharmaShots Interview Pierre Fabre’ Roberta Valenti Shares Insights on Nerlynx (neratinib) for the Treatment of HER2 Early Breast Cancer
VIEWPOINTS

PharmaShots Interview: Pierre Fabre’ Roberta Valenti Shares Insights on Nerlynx (neratinib) for the Treatment of HER2 Early Breast Cancer

In an interview with PharmaShots, Roberta Valenti, Global Medical Director at Pierre Fabre shared her views on Nerlynx (neratinib) in P-II (CONTROL) study & showed improved tolerability with all the investigated diarrhoea prophylaxis strategies, presented at SABCS 2021 Shots: The P-II (CONTROL) study evaluates 6 preventive antidiarrheal prophylaxis options with loperamide for the prevention of neratinib-associated diarrhoea. Patients will receive neratinib (240 mg/day) for 1yr.…
April 27, 2022

Read more

PharmaShots Interview ViiV Healthcare’s Kimberly Smith Shares Insights on Apretude for the Prevention of HIV
VIEWPOINTS

PharmaShots Interview: ViiV Healthcare’s Kimberly Smith Shares Insights on Apretude for the Prevention of HIV

In an interview with PharmaShots, Kimberly Smith, Senior Vice President, Head of Research & Development at ViiV Healthcare shared her views on the US FDA’s approval of the first long-acting injectable option of Apretude for the prevention of HIV The approval is based on the P-IIb/III (HPTN 083/084) trial to evaluate cabotegravir (q8w) vs FTC/TDF (200/300 mg) in 7,700+ patients who…
April 26, 2022

Read more

PharmaShots Interview Janssen’s Soumya D. Chakravarty Shares Insights on Tremfya (guselkumab) for the Treatment of Active Psoriatic Arthritis
VIEWPOINTS

PharmaShots Interview: Janssen’s Soumya D. Chakravarty Shares Insights on Tremfya (guselkumab) for the Treatment of Active Psoriatic Arthritis

In an interview with PharmaShots, Soumya D. Chakravarty, Senior Director, Strategic Lead, Rheumatology Therapeutic Area at Janssen shared his views on the data of Tremfya in the P-IIIb (COSMOS) trial for the treatment of active psoriatic arthritis, published in the Annals of the Rheumatic Diseases The P-IIIb (COSMOS) trial evaluates Tremfya (100mg) vs PBO in a ratio (2:1) in 285 patients with active PsA…
April 25, 2022

Read more

PharmaShots Interview Sanofi’s Chris Soria Shares Insights on Amcenestrant for the Treatment of Breast Cancer
VIEWPOINTS

PharmaShots Interview: Sanofi’s Chris Soria Shares Insights on Amcenestrant for the Treatment of Breast Cancer

In an interview with PharmaShots, Chris Soria, Global Project Head of Amcenestrant at Sanofi shared his views on the updated data of Amcenestrant in the P-I/II (AMEERA-1) study for ER+/HER2−metastatic breast cancer, presented at SABCS 2021 Shots: The P-I/II (AMEERA-1) study evaluated amcenestrant as monothx. & in combination with targeted therapies in postmenopausal women with ER+/HER2- MBC In a pooled analysis of 35…
April 20, 2022

Read more

Load more